Sanofi's diabetes business shrinks again

Last year's stockpiling due to the covid-19 outbreak has had a severe impact on Sanofi's diabetes business in the first quarter of the year. The French pharmaceutical company has been forced to admit that this business leg has shrunk once again.

Photo: CHARLES PLATIAU/Reuters / X00217

The diabetes business leg of French pharmaceutical company Sanofi has decreased in size in the first three months of the year, according to the Q1 quarterly report which was published early Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs